Ascent Scientific launches Amyloid β peptide isoforms - supporting Alzheimer's research
Alzheimer's disease is the most common form of dementia which has no known cure and is thought to be caused by pathogenicity induced by an increased production of β-amyloid peptide. Although the mechanisms involved are not yet fully understood, it is known that β amyloid peptide forms the main constituent of amyloid plaques - characteristically found in Alzheimer's disease patients. In order to support Alzheimer's disease research, Ascent Scientific has launched a number of amyloid β peptide isoforms: Amyloid β (1-42) (human) 42-residue amyloid β-protein fragment; the predominant form of amyloid β found in the brains of people with Alzheimer's disease and Down's syndrome. Neurotoxic. Shown to induce neuronal death via actions at the p75 neurotrophin receptor. Amyloid β (1-40) (human) One of the two main alloforms of the amyloid β peptide widely implicated in Alzheimer's disease. Displays neuroprotective properties preventing neuronal death. Amyloid β (25-35) (human) Highly toxic, synthetic peptide fragment of the amyloid β protein. Displays extremely rapid aggregation and enhanced neurotoxicity. Increases oxidative stress, causes neuronal damage and decreases spatial memory in rats. Amyloid β (42-1) (human) Inactive control for Amyloid β (1-42) peptide (Asc-301), the predominant form of amyloid β implicated in Alzheimer's disease.